News from Decision Resources Group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jul 19, 2017, 09:22 ET Eylea Will Dominate The Wet Age-Related Macular Degeneration Market Until 2018, When Its Share Will Become Threatened By Emerging Products

Decision Resources Group finds that over the next ten years, the market for late age-related macular degeneration (AMD) therapies will become...


Jun 28, 2017, 10:42 ET With Launch of Generic Inhaled Therapies for Asthma and COPD, Devices will Allow Some Drugs to Stand Out

Decision Resources Group finds that practitioners prescribing inhaled therapies prefer simpler devices. Although the diverse array of drug/device...


Jun 27, 2017, 09:12 ET Survey Shows Intensifying Focus on Cost and Demonstration of Value in Increasingly Competitive Orphan Drug Space

Decision Resources Group finds that more than 40% of surveyed U.S. physicians perceive an increase over the last three years in the degree of payer...


Jun 26, 2017, 08:45 ET Acute Heart Failure Treatment Dominated by Therapies Effective at Relieving Symptoms

Decision Resources Group finds that, in the absence of therapies able to improve long-term outcomes, treatment approaches in Acute Heart Failure...


Jun 02, 2017, 14:55 ET Decision Resources Group Appoints Lou Pascarella as Executive Vice President, Global Sales

Decision Resources Group (DRG), a subsidiary of India-based Piramal Enterprises Limited (Piramal), today announced that Lou Pascarella has joined...


Jun 01, 2017, 10:52 ET Costly Atopic Dermatitis Therapies Impact Traditionally Low-Cost Market

Decision Resources Group finds that efficacy in atopic dermatitis patients refractory to topicals and conventional systemics will be a key driver...


May 30, 2017, 08:51 ET Disease-Modifying Therapies: An Unmet Need for Patients with Diabetic Nephropathy

Decision Resources Group finds that approximately 66% of surveyed physicians in the United States and 70% in Europe (United Kingdom, France, and...


May 16, 2017, 12:01 ET Decision Resources Group Consulting Ranks No. 14 on 2017 Top Consulting Firms by Ivy Exec

Ivy Exec has ranked Decision Resources Group Consulting (DRGC) on its 2017 Top Consulting Firms to Work For rankings for the second year in a row....


May 15, 2017, 10:17 ET Poor pharma digital marketing damages credibility with physicians, Manhattan Research study finds

Physicians value useful content from pharma that helps them do their jobs and manage care better, such as quality scientific information, patient...


May 04, 2017, 08:00 ET DRG unveils new innovation in network meta-analysis

A novel web-based interactive 3-dimensional (3-D) tool has been developed by Decision Resources Group Abacus in collaboration with leading...


Mar 16, 2017, 13:00 ET Unmet Need and Opportunity Assessment in Recurrent or Metastatic SCCHN: Are Immune Checkpoint Inhibitors the Answer?

Decision Resources Group finds in a survey of U.S. and European oncologists, that in contrast to many other oncology indications, incidence of...


Mar 16, 2017, 08:30 ET PCSK9 Inhibitors Improve Patient Outcomes, But Will That Convince Payers to Pay for Them?

Decision Resources Group finds that the PCSK9 inhibitor agents are expected to become blockbusters on the back of positive outcomes data, but the...


Mar 15, 2017, 13:30 ET Rising Drug-Resistance Rates Continue to Erode the Utility of Frontline Antibiotics, Driving Uptake of New Antibiotic Brands in the Hospital-Treated Gram-Negative Infections Market

Decision Resources Group finds that the hospital-treated Gram-negative infection (GNI) market continues to be dominated by well-entrenched,...


Mar 15, 2017, 10:05 ET Small but Valuable: How Unmet Need in the Severe Asthma Market is Driving Nucala Sales and Offers Opportunity for Others, Including, Teva, AstraZeneca, Sanofi, and Regeneron

Decision Resources Group finds that Nucala's novel mechanism of action and specific indication for eosinophilic asthma are key drivers behind the...


Mar 14, 2017, 12:57 ET The Volatile Alzheimer's Disease (AD) Pipeline Continues to Disappoint, Continually Reshaping Expectations for the Future Market Outlook

Decision Resources Group closely monitors the ever-changing Alzheimer's disease (AD) market. The last six months have seen clinical trial failures...


Mar 14, 2017, 08:45 ET Decision Resources Group's Stephanie Stadlin Named a "Rising Star" by Consulting Magazine

Decision Resources Group (DRG) is pleased to announce that Stephanie Stadlin has been selected as one of Consulting Magazine's 35 Rising Stars of...


Jan 25, 2017, 09:28 ET U.S. Health Policy Analysts Available To Comment On The District Court Ruling Rejecting Aetna-Humana Merger

Principal Analysts Bill Melville and Paula Wade are available to discuss the U.S. District Court's decision to reject Aetna's $37 billion merger...


Jan 12, 2017, 10:30 ET Live Election Analysis Webinar, Open to Members of the press - DRG analysts explore the likely Healthcare industry implications of the 2016 US Election

As the US prepares for the inauguration of Donald Trump, and Congress is poised to enact sweeping changes to the Affordable Care Act, Decision...


Dec 14, 2016, 08:07 ET DRG Abacus leads the way in the publication of meta-analysis and NMA capabilities to support reimbursement activities globally

A recently published paper analysing global research collaborations for Network Meta-Analysis (NMA) has placed DRG Abacus1 as the third most...


Dec 01, 2016, 08:45 ET DRG Forecasts New Treatment Options Will Revolutionize the Management Of Hemophilia A and Hemophilia With Inhibitors; Hemophilia B Patients are Relatively Well Served.

BURLINGTON, Mass., Dec. 1, 2016 /PRNewswire/ -- Decision Resources Group – Hemophilia patients will have a greater variety of treatment options...


Nov 29, 2016, 06:00 ET DRG and Zephyr Health Announce Partnership to Optimize the Commercial and Market Access Experience for Pharma Stakeholders

Decision Resources Group (DRG), a leading provider of proprietary data products and solutions to the healthcare industry, and Zephyr Health, the...


Nov 14, 2016, 11:29 ET Analysts Available to Comment on the Implications of the Recent US Presidential Election and the Future of the Affordable Care Act and the US Healthcare Industry

Principal Analysts Bill Melville and Paula Wade and Market Analyst Joyce Caruthers are available to discuss the Presidential election and its...


Nov 14, 2016, 10:09 ET Europe has developed into an emerging market for next-generation cosmetic threads fueled by high aesthetic consciousness, recent product innovation, and patient demand for minimally invasive cosmetic procedures

Decision Resources Group finds that demand for a minimally invasive cost-effective alternative to the surgical facelift, favorable demographics,...


Nov 03, 2016, 09:13 ET New MS Therapies & HTA Bodies: What's Driving Such High Rates of Positive Evaluation?

Decision Resources Group finds that 88 percent of health technology assessment (HTA) reviews that examined several recently-launched multiple...


Nov 02, 2016, 09:03 ET The Non-Hodgkin's Lymphoma Drug Market Will Experience Significant Growth, Reaching Over $19 Billion by 2025

New drug approvals have fundamentally changed the non-Hodgkin's Lymphoma (NHL) and chronic lymphocytic leukemia (CLL) market landscape. As...